An Open-Label Drug Interaction Study to Assess the Pharmacokinetics of JNJ-42847922 When Administered Alone and in Combination With Rifampin in Healthy Male and Female Subjects

Trial Profile

An Open-Label Drug Interaction Study to Assess the Pharmacokinetics of JNJ-42847922 When Administered Alone and in Combination With Rifampin in Healthy Male and Female Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 10 May 2016

At a glance

  • Drugs Seltorexant (Primary) ; Rifampicin
  • Indications Insomnia; Major depressive disorder
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 04 May 2016 Status changed from recruiting to completed.
    • 18 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov.
    • 04 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top